• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

口服阿昔洛韦在生殖器疱疹患者中的药代动力学。

Pharmacokinetics of orally administered acyclovir in patients with herpes progenitalis.

作者信息

Van Dyke R B, Connor J D, Wyborny C, Hintz M, Keeney R E

出版信息

Am J Med. 1982 Jul 20;73(1A):172-5. doi: 10.1016/0002-9343(82)90085-7.

DOI:10.1016/0002-9343(82)90085-7
PMID:7102701
Abstract

The pharmacokinetics of acyclovir administrated orally in a dose of 200 mg every four hours, five times a day to adults with herpes progenitalis was determined. Peak plasma acyclovir levels are found 1.5 to 1.75 hours after oral administration; peak levels range from 1.4 to 4.0 microM with a mean of 2.5 microM. Acyclovir levels in saliva are well correlated with simultaneous plasma levels, saliva levels being approximately 13 percent of plasma levels. Simultaneous plasma and vaginal secretion acyclovir levels are poorly correlated; peak levels in vaginal secretions range from 0.5 to 3.6 microM.

摘要

对患有生殖器疱疹的成年人,以每四小时200毫克、一天五次的剂量口服阿昔洛韦后的药代动力学进行了测定。口服给药后1.5至1.75小时可测得血浆阿昔洛韦水平峰值;峰值水平在1.4至4.0微摩尔之间,平均为2.5微摩尔。唾液中的阿昔洛韦水平与同时测得的血浆水平密切相关,唾液水平约为血浆水平的13%。血浆和阴道分泌物中阿昔洛韦的同步水平相关性较差;阴道分泌物中的峰值水平在0.5至3.6微摩尔之间。

相似文献

1
Pharmacokinetics of orally administered acyclovir in patients with herpes progenitalis.口服阿昔洛韦在生殖器疱疹患者中的药代动力学。
Am J Med. 1982 Jul 20;73(1A):172-5. doi: 10.1016/0002-9343(82)90085-7.
2
Controlled trial of oral acyclovir in the therapy of recurrent herpes simplex genitalis. A preliminary report.口服阿昔洛韦治疗复发性单纯疱疹性生殖器病的对照试验。初步报告。
Am J Med. 1982 Jul 20;73(1A):338-41. doi: 10.1016/0002-9343(82)90119-x.
3
Double-blind controlled trial of topical acyclovir in genital herpes simplex virus infections.局部用阿昔洛韦治疗单纯疱疹病毒生殖器感染的双盲对照试验
Am J Med. 1982 Jul 20;73(1A):326-34. doi: 10.1016/0002-9343(82)90117-6.
4
Acyclovir treatment of experimental genital herpes simplex virus infections.阿昔洛韦治疗实验性单纯疱疹病毒生殖器感染
Am J Med. 1982 Jul 20;73(1A):100-8. doi: 10.1016/0002-9343(82)90073-0.
5
Neonatal acyclovir pharmacokinetics in patients with herpes virus infections.
Am J Med. 1982 Jul 20;73(1A):210-4. doi: 10.1016/0002-9343(82)90093-6.
6
Oral acyclovir in the treatment of genital herpes. Preliminary report of a multicenter trial.口服阿昔洛韦治疗生殖器疱疹。一项多中心试验的初步报告。
Am J Med. 1982 Jul 20;73(1A):335-7. doi: 10.1016/0002-9343(82)90118-8.
7
Single-dose pharmacokinetics of acyclovir.阿昔洛韦的单剂量药代动力学。
Antimicrob Agents Chemother. 1981 Apr;19(4):608-12. doi: 10.1128/AAC.19.4.608.
8
Pharmacokinetics of acyclovir in the term human pregnancy and neonate.
Am J Obstet Gynecol. 1991 Feb;164(2):569-76. doi: 10.1016/s0002-9378(11)80023-2.
9
Pharmacokinetics of acyclovir in humans following intravenous administration. A model for the development of parenteral antivirals.静脉注射后阿昔洛韦在人体内的药代动力学。一种肠外抗病毒药物研发模型。
Am J Med. 1982 Jul 20;73(1A):165-71. doi: 10.1016/0002-9343(82)90084-5.
10
Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes.口服阿昔洛韦治疗初发性和复发性生殖器疱疹的疗效
Lancet. 1982 Sep 11;2(8298):571-3. doi: 10.1016/s0140-6736(82)90658-4.

引用本文的文献

1
Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2.目前用于治疗单纯疱疹病毒 1 型和 2 型感染的药物。
Viruses. 2021 Jun 25;13(7):1228. doi: 10.3390/v13071228.
2
Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model.用于预防艾滋病毒、单纯疱疹病毒和意外怀孕的新型多功能豆荚式阴道环:猕猴模型中的药代动力学评估
PLoS One. 2017 Oct 5;12(10):e0185946. doi: 10.1371/journal.pone.0185946. eCollection 2017.
3
Safety and pharmacokinetics of aciclovir in women following release from a silicone elastomer vaginal ring.
硅酮弹性体阴道环释放后女性阿昔洛韦的安全性和药代动力学。
J Antimicrob Chemother. 2012 Aug;67(8):2005-12. doi: 10.1093/jac/dks151. Epub 2012 May 3.
4
Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies.多用途预防技术:预防HIV-1、HSV-2和意外怀孕的生物医学工具。
Infect Dis Obstet Gynecol. 2011;2011:1-10. doi: 10.1155/2011/429403. Epub 2011 Aug 9.
5
Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.阿昔洛韦或伐昔洛韦抑制单纯疱疹病毒 2 型治疗不会在 HIV-1/HSV-2 双重感染人群中选择出特定的 HIV-1 耐药性。
J Infect Dis. 2011 Jan 1;203(1):117-21. doi: 10.1093/infdis/jiq013.
6
Valacyclovir pharmacokinetics and exploratory pharmacodynamics in young adults with Epstein-Barr virus infectious mononucleosis.伐昔洛韦在 EBV 传染性单核细胞增多症青年患者中的药代动力学和探索性药效学。
J Clin Pharmacol. 2010 Jul;50(7):734-42. doi: 10.1177/0091270009351884. Epub 2009 Nov 6.
7
Clinical pharmacokinetics of acyclovir.阿昔洛韦的临床药代动力学
Clin Pharmacokinet. 1983 May-Jun;8(3):187-201. doi: 10.2165/00003088-198308030-00001.
8
Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.阿昔洛韦。对其药效学特性及治疗效果的综述。
Drugs. 1983 Nov;26(5):378-438. doi: 10.2165/00003495-198326050-00002.
9
Oral acyclovir therapy of genital herpes simplex virus type 2 infections in guinea pigs.豚鼠2型单纯疱疹病毒生殖器感染的口服阿昔洛韦治疗
Antimicrob Agents Chemother. 1985 Feb;27(2):167-71. doi: 10.1128/AAC.27.2.167.
10
Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.阿昔洛韦。对其抗病毒活性、药代动力学特性及治疗效果的最新综述。
Drugs. 1989 Mar;37(3):233-309. doi: 10.2165/00003495-198937030-00002.